{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:15:20Z","timestamp":1783289720988,"version":"3.54.6"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-026-00307-6","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:03:15Z","timestamp":1783288995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PET\/CT contouring techniques in neuroendocrine neoplasms: a state-of-the-art scoping review"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-3421","authenticated-orcid":false,"given":"Jacky WT","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"7","key":"307_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.119.234062","volume":"61","author":"LC Adams","year":"2020","unstructured":"Adams LC, Bressem KK, Brangsch J, Reimann C, Nowak K, Brenner W, Makowski MR (2020) Quantitative 3D assessment of 68Ga-DOTATOC PET\/MRI with diffusion-weighted imaging to assess imaging markers for Gastroenteropancreatic neuroendocrine tumors: preliminary results. J Nucl Med 61(7):1021\u20131027. https:\/\/doi.org\/10.2967\/jnumed.119.234062","journal-title":"J Nucl Med"},{"issue":"9","key":"307_CR2","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.7150\/thno.98053","volume":"14","author":"A Akhavanallaf","year":"2024","unstructured":"Akhavanallaf A, Joshi S, Mohan A, Worden FP, Krauss JC, Zaidi H, Frey K, Suresh K, Dewaraja YK, Wong KK (2024) Enhancing precision: a predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers. Theranostics 14(9):3708\u20133718. https:\/\/doi.org\/10.7150\/thno.98053","journal-title":"Theranostics"},{"key":"307_CR3","doi-asserted-by":"publisher","unstructured":"Alberts I, Sari H, Mingels C, Afshar-Oromieh A, Pyka T, Shi K, Rominger A (2023) Long-axial field-of-view PET\/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients. Cancer Imag 23(1):23(1).10.1186\/s40644\u2013023\u201300540\u20133. https:\/\/doi.org\/10.1186\/s40644-023-00540-3","DOI":"10.1186\/s40644-023-00540-3"},{"key":"307_CR4","doi-asserted-by":"publisher","first-page":"1523862","DOI":"10.3389\/fmed.2025.1523862","volume":"12","author":"A Aouf","year":"2025","unstructured":"Aouf A, Speicher T, Blickle A, Bastian MB, Burgard C, Rosar F, Ezziddin S, Sabet A (2025) Prediction of lesion-based response to PRRT using baseline somatostatin receptor PET. Front. Med 12:1523862. https:\/\/doi.org\/10.3389\/fmed.2025.1523862","journal-title":"Front. Med"},{"key":"307_CR5","doi-asserted-by":"publisher","unstructured":"Bezzi C, Mapelli P, Ghezzo S, Muffatti F, Schiavo Lena M, Andreasi V et al (2023) [68Ga]Ga-DOTATOC PET radiomics supports lymph node metastases detection for accurate surgical planning of well-differentiated pancreatic neuroendocrine tumours patients. Eur J Nucl Med Mol Imag 50(Supplement 1):S510\u2013S1. https:\/\/doi.org\/10.1007\/s00259-023-06333-x","DOI":"10.1007\/s00259-023-06333-x"},{"issue":"6","key":"307_CR6","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1002\/cam4.1507","volume":"7","author":"W Cai","year":"2018","unstructured":"Cai W, Tan Y, Ge W, Ding K, Hu H (2018) Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med 7(6):2699\u20132709. https:\/\/doi.org\/10.1002\/cam4.1507","journal-title":"Cancer Med"},{"issue":"11","key":"307_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2967\/jnumed.120.258392","volume":"62","author":"EA Carlsen","year":"2021","unstructured":"Carlsen EA, Johnbeck CB, Loft M, Pfeifer A, Oturai P, Langer SW, Knigge U, Ladefoged CN, Kjaer A (2021) Semiautomatic tumor delineation for evaluation of 64Cu-DOTATATE PET\/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume. J Nucl Med 62(11):1564\u20131570. https:\/\/doi.org\/10.2967\/jnumed.120.258392","journal-title":"J Nucl Med"},{"issue":"1","key":"307_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13550-022-00901-2","volume":"12","author":"EA Carlsen","year":"2022","unstructured":"Carlsen EA, Lindholm K, Hindsholm A, Gaede M, Ladefoged CN, Loft M, Johnbeck CB, Langer SW, Oturai P, Knigge U, Kjaer A, Andersen FL (2022) A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET\/CT of patients with neuroendocrine neoplasms. EJNMMI Res 12(1):30. https:\/\/doi.org\/10.1186\/s13550-022-00901-2","journal-title":"EJNMMI Res"},{"key":"307_CR9","doi-asserted-by":"publisher","unstructured":"Chaban A, Brosch-Lenz J, Song Y, Dinkel V, Bodei L, Weber W (2023) Optimized segmentation of neuroendocrine tumor lesions on somatostatin receptor PET\/CT imaging for therapy response assessment. Eur J Nucl Med Mol Imag 50(Supplement 1):S134\u2013S5. https:\/\/doi.org\/10.1007\/s00259-023-06333-x","DOI":"10.1007\/s00259-023-06333-x"},{"key":"307_CR10","unstructured":"Chan D, Mokhtar S, Bernard E, Diakos C, Sabahi Z, Pavlakis N et al Dual threshold contouring for [68Ga]DOTATATE PET and correlation with overall survival (OS) in patients with neuroendocrine neoplasia (NEN). In 22nd Annual ENETs Conference2025, pp 116"},{"issue":"11","key":"307_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/onco.13923","volume":"26","author":"DL Chan","year":"2021","unstructured":"Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S (2021) Temozolomide in Grade 3 Gastroenteropancreatic neuroendocrine neoplasms: a Multicenter retrospective review. The Oncologist 26(11):950\u2013955. https:\/\/doi.org\/10.1002\/onco.13923","journal-title":"The Oncologist"},{"issue":"11\u201312","key":"307_CR12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1159\/000504673","volume":"110","author":"DL Chan","year":"2020","unstructured":"Chan DL, Bernard EJ, Schembri G, Roach PJ, Johnson M, Pavlakis N, Clarke S, Bailey D (2020) High metabolic tumour volume on 18-fluorodeoxyglucose Positron Emission Tomography Predicts poor survival from neuroendocrine neoplasms. Neuroendocrinology 110(11\u201312):950\u2013958. https:\/\/doi.org\/10.1159\/000504673","journal-title":"Neuroendocrinology"},{"issue":"7","key":"307_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.2967\/jnumed.124.269031","volume":"66","author":"DL Chan","year":"2025","unstructured":"Chan DL, Hayes A, Karfis I, Conner A, Mileva M, Bernard E, Navalkissoor S, Gnanasekaran G, Clarke SJ, Roach PJ, Flamen P, Caplin ME, Pavlakis N, Toumpanakis C, Bailey DL (2025) [18F]FDG metabolic tumor volume as a prognostic marker in neuroendocrine Neoplasm: a Multicenter study. J Nucl Med 66(7):1012\u20131017. https:\/\/doi.org\/10.2967\/jnumed.124.269031","journal-title":"J Nucl Med"},{"issue":"2","key":"307_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2967\/jnumed.123.266346","volume":"65","author":"DL Chan","year":"2024","unstructured":"Chan DL, Hayes AR, Karfis I, Conner A, Mileva M, Bernard E, Schembri G, Navalkissoor S, Gnanasegaran G, Pavlakis N, Marin C, Vanderlinden B, Flamen P, Roach P, Caplin ME, Toumpanakis C, Bailey DL (2024) [18F]FDG PET\/CT\u2013avid discordant volume as a biomarker in patients with Gastroenteropancreatic neuroendocrine neoplasms: a Multicenter study. J Nucl Med 65(2):185. https:\/\/doi.org\/10.2967\/jnumed.123.266346","journal-title":"J Nucl Med"},{"issue":"5","key":"307_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DLH Chan","year":"2017","unstructured":"Chan DLH, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL (2017) Dual somatostatin Receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel Grading scheme with prognostic significance. Theranostics 7(5):1149\u20131158. https:\/\/doi.org\/10.7150\/thno.18068","journal-title":"Theranostics"},{"issue":"7","key":"307_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou F-S, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O\u2019Reilly EM, Meyerhardt JA (2025) Phase 3 trial of Cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med 392(7):653\u2013665. https:\/\/doi.org\/10.1056\/NEJMoa2403991","journal-title":"N Engl J Med"},{"issue":"2","key":"307_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1109\/83.902291","volume":"10","author":"TF Chan","year":"2001","unstructured":"Chan TF, Vese LA (2001) Active contours without edges. IEEE Trans. Image Process 10(2):266\u2013277. https:\/\/doi.org\/10.1109\/83.902291","journal-title":"IEEE Trans. Image Process"},{"issue":"2","key":"307_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00259-022-05971-x","volume":"50","author":"L Chen","year":"2023","unstructured":"Chen L, Jumai N, He Q, Liu M, Lin Y, Luo Y, Wang Y, Chen M-H, Zeng Z, Zhang X, Zhang N (2023) The role of quantitative tumor burden based on [68Ga]Ga-DOTA-NOC PET\/CT in well-differentiated neuroendocrine tumors: beyond prognosis. Eur J Nucl Med Mol Imag 50(2):525\u2013534. https:\/\/doi.org\/10.1007\/s00259-022-05971-x","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"307_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1159\/000530771","volume":"114","author":"Z Cheng","year":"2023","unstructured":"Cheng Z, Zou S, Zhou J, Song S, Zhu Y, Zhao J, Zhu X (2023) Prognostic value of somatostatin receptor-derived volumetric parameters from a Hybrid Standardized uptake value thresholding method in patients with 68Ga-DOTATATE-Avid Stage IV neuroendocrine neoplasms: a Preliminary study. Neuroendocrinology 114(9):805\u2013815. https:\/\/doi.org\/10.1159\/000530771","journal-title":"Neuroendocrinology"},{"issue":"6","key":"307_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC (2016) 68Ga-DOTATATE compared with 111In-DTPA-Octreotide and conventional imaging for pulmonary and Gastroenteropancreatic neuroendocrine tumors: a Systematic review and meta-analysis. J Nucl Med 57(6):872\u2013878. https:\/\/doi.org\/10.2967\/jnumed.115.165803","journal-title":"J Nucl Med"},{"key":"307_CR21","doi-asserted-by":"publisher","unstructured":"Dias AH, Hansen AK, Munk OL, Gormsen LC (2022) Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients. EJNMMI Res 12(1):12.10.1186\/s13550\u2013022\u201300884\u20130. https:\/\/doi.org\/10.1186\/s13550-022-00884-0","DOI":"10.1186\/s13550-022-00884-0"},{"key":"307_CR22","unstructured":"Dupuis A, Rousseau E, Turcotte E, Guerin B, Richard G, Croteau E et al (2024) Radiomic analysis of 68Ga-DOTATATE PET to characterize growth potential of neuroendocrine cancer lesions. J Nucl Med 65(Supplement 2)"},{"key":"307_CR24","doi-asserted-by":"publisher","unstructured":"Fedrigo R, Harsini S, Murtha L, Vasconcelos JPS, Uribe C, Wilson D, Benard F, Alberts I, Martineau P, Loree JM (2025) Octreotide scintigraphy versus DOTATOC PET: concordance of Krenning scores and implications on PRRT treatment eligibility. JCO 43(16_suppl). https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e16339","DOI":"10.1200\/JCO.2025.43.16_suppl.e16339"},{"issue":"8","key":"307_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/MNM.0000000000001861","volume":"45","author":"N Filizoglu","year":"2024","unstructured":"Filizoglu N, Ozguven S, Akin Telli T, Ones T, Dede F, Turoglu HT, Erdil TY (2024) Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68Ga-DOTATATE positron emission tomography\/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors. Nucl Med Commun 45(8):736\u2013744. https:\/\/doi.org\/10.1097\/MNM.0000000000001861","journal-title":"Nucl Med Commun"},{"issue":"10","key":"307_CR26","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2967\/jnumed.121.262928","volume":"63","author":"R Fonti","year":"2022","unstructured":"Fonti R, Panico M, Pellegrino S, Pulcrano A, Vastarella LA, Torbati AHM, Giuliano M, Palmieri G, De Placido S, Del Vecchio S (2022) Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET\/CT using coefficient of variation in patients with neuroendocrine tumors. J Nucl Med 63(10):1509\u20131514. https:\/\/doi.org\/10.2967\/jnumed.121.262928","journal-title":"J Nucl Med"},{"issue":"5","key":"307_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.semnuclmed.2025.04.005","volume":"55","author":"MD Franco","year":"2025","unstructured":"Franco MD, Lamberti G, Campana D, Ambrosini V (2025) Molecular imaging for response assessment of neuroendocrine tumors (NET). Semin Nucl Med 55(5):754\u2013765. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.04.005","journal-title":"Semin Nucl Med"},{"key":"307_CR28","doi-asserted-by":"publisher","first-page":"107327482311523","DOI":"10.1177\/10732748231152328","volume":"30","author":"R Gallicchio","year":"2023","unstructured":"Gallicchio R, Giordano A, Milella M, Storto R, Pellegrino T, Nardelli A, Nappi A, Tarricone L, Storto G (2023) Ga-68-Edotreotide Positron Emission Tomography\/Computed Tomography somatostatin receptors tumor volume Predicts outcome in patients with primary Gastroenteropancreatic neuroendocrine tumors. Cancer Control: J Moffitt Cancer Cent: J The Moffitt Cancer Cent 30:10732748231152328. https:\/\/doi.org\/10.1177\/10732748231152328","journal-title":"Cancer Control: J Moffitt Cancer Cent: J The Moffitt Cancer Cent"},{"key":"307_CR29","doi-asserted-by":"publisher","unstructured":"Galne A, Enqvist O, Sundl\u00f6v A, Valind K, Minarik D, Tr\u00e4gardh E (2023) AI-based quantification of whole-body tumour burden on somatostatin receptor PET\/CT. Eur J Hybrid Imag 7(1):7(1).10.1186\/s41824\u2013023\u201300172\u20137. https:\/\/doi.org\/10.1186\/s41824-023-00172-7","DOI":"10.1186\/s41824-023-00172-7"},{"key":"307_CR30","doi-asserted-by":"publisher","unstructured":"Gonzalez Martinez M, Piana Bezaury A, Perez Diaz I, Olarte Casas M (2023) 18F-AlF-NOTA-Octreotide PET\/CT: Krenning\u2019s score and tumor burden influence by tumor volume and total lesion activity. Eur J Nucl Med Mol Imag 50(Supplement 1):S507. https:\/\/doi.org\/10.1007\/s00259-023-06333-x","DOI":"10.1007\/s00259-023-06333-x"},{"key":"307_CR31","doi-asserted-by":"crossref","unstructured":"Grage R, Dudgeon M, Sharma A, Parent E (2024) [68Ga] DOTA-TATE (NETSpot) PET\/CT imaging of pulmonary neuroendocrine tumors. In NANETS, 2024 Symposium, Chicago","DOI":"10.1530\/endoabs.98.C18"},{"issue":"1","key":"307_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13550-024-01168-5","volume":"14","author":"F Haque","year":"2024","unstructured":"Haque F, Carrasquillo JA, Turkbey EB, Mena E, Lindenberg L, Eclarinal PC, Nilubol N, Choyke PL, Floudas CS, Lin FI, Turkbey B, Harmon SA (2024) An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-body 68Ga- DOTATATE PET\/CT. EJNMMI Res 14(1):103. https:\/\/doi.org\/10.1186\/s13550-024-01168-5","journal-title":"EJNMMI Res"},{"issue":"5","key":"307_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"Haug A, Auernhammer CJ, Wangler B, Tiling R, Schmidt G, Goke B, Bartenstein P, P\u00f6pperl G (2009) Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imag 36(5):765\u2013770. https:\/\/doi.org\/10.1007\/s00259-008-1030-8","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"307_CR34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, Cumming P, Bartenstein P, Tiling R, Hacker M (2010) 68Ga-DOTATATE PET\/CT for the Early Prediction of response to somatostatin receptor\u2013mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51(9):1349\u20131356. https:\/\/doi.org\/10.2967\/jnumed.110.075002","journal-title":"J Nucl Med"},{"issue":"4","key":"307_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12149-023-01899-w","volume":"38","author":"M Hotta","year":"2024","unstructured":"Hotta M, Sonni I, Thin P, Nguyen K, Gardner L, Ciuca L, Hayrapetian A, Lewis M, Lubin D, Allen-Auerbach M (2024) Visual and whole-body quantitative analyses of 68Ga-DOTATATE PET\/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE. Ann Nucl Med 38(4):296\u2013304. https:\/\/doi.org\/10.1007\/s12149-023-01899-w","journal-title":"Ann Nucl Med"},{"issue":"3","key":"307_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s13139-013-0262-0","volume":"48","author":"HS Kim","year":"2014","unstructured":"Kim HS, Choi JY, Choi DW, Lim HY, Lee JH, Hong SP, Cho YS, Lee K-H, Kim B-T (2014) Prognostic value of volume-based metabolic parameters measured by 18F-FDG PET\/CT of pancreatic neuroendocrine tumors. Nucl Med Mol Imag 48(3):180\u2013186. https:\/\/doi.org\/10.1007\/s13139-013-0262-0","journal-title":"Nucl Med Mol Imag"},{"issue":"6","key":"307_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","volume":"31","author":"PE Kinahan","year":"2010","unstructured":"Kinahan PE, Fletcher JW (2010) Positron Emission Tomography-Computed Tomography Standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MRI 31(6):496\u2013505.10.1053\/j.sult.2010.10.001. https:\/\/doi.org\/10.1053\/j.sult.2010.10.001","journal-title":"Semin Ultrasound CT MRI"},{"key":"307_CR38","unstructured":"Kong G, Sutherland D, Roselt P, Hicks R, Haskali M, Akhurst T (2023) Evaluation of [68Ga]Ga-DOTA-CP04 imaging in cholecystokinin-2 receptors (CCK-2R) positive tumors. J Nucl Med 64(Supplement 1)"},{"issue":"3","key":"307_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U, Giesel FL (2015) SUV of [68Ga]DOTATOC-PET\/CT Predicts response Probability of PRRT in neuroendocrine tumors. Mol Imag Biol 17(3):313\u2013318. https:\/\/doi.org\/10.1007\/s11307-014-0795-3","journal-title":"Mol Imag Biol"},{"key":"307_CR40","doi-asserted-by":"publisher","unstructured":"Krebs S, Lafontaine D, Bodei L, Mayerhoefer ME, Humm J, Schoder H (2023) Development of a semi-automatic platform for whole body tumor segmentation and radiomic Feature Extraction from 68Ga-DOTATATE PET\/CT using TriDFusion (3DF). Eur J Nucl Med Mol Imag 50(Supplement 1):S508\u2013S9. https:\/\/doi.org\/10.1007\/s00259-023-06333-x","DOI":"10.1007\/s00259-023-06333-x"},{"issue":"2","key":"307_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12020-022-03160-2","volume":"78","author":"M Lelievre","year":"2022","unstructured":"Lelievre M, Triumbari EKA, Brixi H, Perrier M, Cadiot G, Deguelte S, Morland D (2022) Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors. Endocrine 78(2):380\u2013386. https:\/\/doi.org\/10.1007\/s12020-022-03160-2","journal-title":"Endocrine"},{"issue":"1","key":"307_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40658-021-00367-6","volume":"8","author":"V Liberini","year":"2021","unstructured":"Liberini V, De Santi B, Rampado O, Gallio E, Dionisi B, Ceci F, Polverari G, Thuillier P, Molinari F, Deandreis D (2021) Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET\/CT images of neuroendocrine tumor. EJNMMI Phys 8(1):21. https:\/\/doi.org\/10.1186\/s40658-021-00367-6","journal-title":"EJNMMI Phys"},{"key":"307_CR43","doi-asserted-by":"publisher","unstructured":"Lin F, Del J, Carrasquillo J, Shamis I, Zou J, Turkbey B, Jha A, Klubo J, Adler S, Mena E, Lindenberg L, Chen C, Herscovitch P, Millo C, Pacak K (2023) Ratio of total uptake volume on DOTATATE vs FDG PET as a predictive marker of treatment efficacy of Lu-177-DOTATATE in metastatic pheochromocytoma. EJEA 64(Supplement 1). https:\/\/doi.org\/10.1530\/endoabs.98.C21","DOI":"10.1530\/endoabs.98.C21"},{"key":"307_CR44","doi-asserted-by":"publisher","unstructured":"Linguanti F, Abenavoli EM, Lombardo A, Briganti V, Mungai F, Antonuzzo L et al (2023) 68Ga-DOTA peptides PET\/CT radiomic parameters useful to differentiate para-physiological uptake in pancreatic uncinate process from pancreatic NET. Eur J Nucl Med Mol Imag 50(Supplement 1):S514\u2013S5. https:\/\/doi.org\/10.1007\/s00259-023-06333-x","DOI":"10.1007\/s00259-023-06333-x"},{"issue":"6","key":"307_CR45","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/icvts\/ivz009","volume":"28","author":"F Lococo","year":"2019","unstructured":"Lococo F, Rapicetta C, Mengoli MC, Filice A, Paci M, Di Stefano T, Coruzzi C, Versari A (2019) Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features. Interact Cardiovasc Thorac Surg 28(6):957\u2013960. https:\/\/doi.org\/10.1093\/icvts\/ivz009","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"307_CR46","unstructured":"Lokre O, Weisman A, Munian-Govindan R, Perk T, Liu E (2023) Cross-radiotracer generalizability of automated lesion detection via CNN: pilot study in 64Cu- and 68Ga-DOTATATE PET\/CT. J Nucl Med 64(Supplement 1)"},{"issue":"2","key":"307_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/diagnostics11020192","volume":"11","author":"P Mapelli","year":"2021","unstructured":"Mapelli P, Partelli S, Salgarello M, Doraku J, Muffatti F, Lena MS, Pasetto S, Bezzi C, Bettinardi V, Andreasi V, Rancoita PMV, Gianolli L, Picchio M, Falconi M (2021) Dual tracer 68Ga-DOTATOC and 18F-FDG PET improve Preoperative evaluation of aggressiveness in resectable pancreatic neuroendocrine neoplasms. DIAGNOSTICS 11(2):192. https:\/\/doi.org\/10.3390\/diagnostics11020192","journal-title":"DIAGNOSTICS"},{"issue":"12","key":"307_CR48","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3390\/cancers17121937","volume":"17","author":"MG Maratta","year":"2025","unstructured":"Maratta MG, Al-Toubah T, Montilla-Soler J, Pelle E, Haider M, El-Haddad G, Strosberg J (2025 Symposium; Chicago 2024.Somatostatin receptor expression of Gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis in the era of somatostatin receptor PET imaging. Cancers 17(12):1937. https:\/\/doi.org\/10.3390\/cancers17121937","journal-title":"Cancers"},{"issue":"10","key":"307_CR49","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2967\/jnumed.124.267982","volume":"65","author":"U Metser","year":"2024","unstructured":"Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, Singh S (2024) Dual somatostatin receptor\/ 18F-FDG PET\/CT imaging in patients with well-differentiated, Grade 2 and 3 Gastroenteropancreatic neuroendocrine tumors. J Nucl Med 65(10):1591\u20131596. https:\/\/doi.org\/10.2967\/jnumed.124.267982","journal-title":"J Nucl Med"},{"issue":"12","key":"307_CR50","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.124.268288","volume":"65","author":"K Michalski","year":"2024","unstructured":"Michalski K, Kosmala A, Hartrampf PE, Heinrich M, Serfling SE, Schlotelburg W, Buck AK, Meining A, Werner RA, Weich A (2024) [18F]FDG and [68Ga]Ga-FAPI-04\u2013Directed imaging for outcome Prediction in patients with high-Grade neuroendocrine neoplasms. J Nucl Med 65(12):1899\u20131903. https:\/\/doi.org\/10.2967\/jnumed.124.268288","journal-title":"J Nucl Med"},{"key":"307_CR51","unstructured":"Michalski K, Kosmala A, Schlotelburg W, Hartrampf P, Serfling S, Buck A et al (2024) Prognostic impact of dual tracer PET\/CT in patients with neuroendocrine neoplasms: FDG and FAP-directed imaging for outcome prediction. J Nucl Med 65(Supplement 2)"},{"issue":"2","key":"307_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11307-024-01899-w","volume":"26","author":"K Michalski","year":"2024","unstructured":"Michalski K, Schlotelburg W, Hartrampf P, Heinrich M, Serfling S, Buck AK, Werner RA, Kosmala A, Weich A (2024) Volumetric parameters derived from CXCR4-Directed PET\/CT predict outcome in patients with gastrointestinal neuroendocrine carcinomas. Mol Imag Biol 26(2):344\u2013350. https:\/\/doi.org\/10.1007\/s11307-024-01899-w","journal-title":"Mol Imag Biol"},{"issue":"1","key":"307_CR53","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4149\/neo_2018_180328N209","volume":"66","author":"J Ohnona","year":"2019","unstructured":"Ohnona J, Nataf V, Gauthe M, Balogova S, Belissant Benesty O, Zhang-Yin J, Talbot J-N, Montravers F (2019) Prognostic value of functional tumor burden on 68Ga-DOTATOC PET\/CT in patients with pancreatic neuro-endocrine tumors. Neoplasma 66(1):140\u2013148. https:\/\/doi.org\/10.4149\/neo_2018_180328N209","journal-title":"Neoplasma"},{"issue":"8","key":"307_CR54","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2967\/jnumed.117.199935","volume":"59","author":"F Orlhac","year":"2018","unstructured":"Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, Soussan M, Frouin F, Frouin V, Buvat I (2018) A postreconstruction harmonization method for Multicenter radiomic studies in PET. J Nucl Med 59(8):1321\u20131328. https:\/\/doi.org\/10.2967\/jnumed.117.199935","journal-title":"J Nucl Med"},{"issue":"10","key":"307_CR55","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, Laidley D, Anconina R, Liu A, Metser U (2021) Quantitative 68Ga-Dotatate PET\/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-Dotatate. J Nucl Med 62(10):1406\u20131414. https:\/\/doi.org\/10.2967\/jnumed.120.256727","journal-title":"J Nucl Med"},{"issue":"1","key":"307_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4274\/mirt.galenos.2021.37268","volume":"30","author":"S Ozguven","year":"2021","unstructured":"Ozguven S, Filizoglu N, Kesim S, Oksuzoglu K, Sen F, Ones T, \u0130nan\u0131r S, Turo\u011flu HT, Erdil TY (2021) Physiological biodistribution of 68Ga-DOTA-TATE in Normal subjects. Mirt 30(1):39\u201346.10.4274\/mirt.galenos.2021.37268. https:\/\/doi.org\/10.4274\/mirt.galenos.2021.37268","journal-title":"Mirt"},{"issue":"5","key":"307_CR57","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s11307-023-01832-7","volume":"25","author":"Y-J Park","year":"2023","unstructured":"Park Y-J, Park YS, Kim ST, Hyun SH (2023) A machine learning Approach using [18F]FDG PET-Based radiomics for Prediction of tumor Grade and prognosis in pancreatic neuroendocrine tumor. Mol Imag Biol 25(5):897\u2013910. https:\/\/doi.org\/10.1007\/s11307-023-01832-7","journal-title":"Mol Imag Biol"},{"issue":"6","key":"307_CR58","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/biomedicines13061286","volume":"13","author":"S Pellegrino","year":"2025","unstructured":"Pellegrino S, Panico M, Bologna R, Morra R, Servetto A, Bianco R, Del Vecchio S, Fonti R (2025) Texture analysis of 68Ga-DOTATOC PET\/CT images for the Prediction of outcome in patients with neuroendocrine tumors. Biomedicines 13(6):1286. https:\/\/doi.org\/10.3390\/biomedicines13061286","journal-title":"Biomedicines"},{"issue":"1","key":"307_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40644-025-00899-5","volume":"25","author":"S Raad","year":"2025","unstructured":"Raad S, Al-Fatlawi A, Wise CL, Fottner C, Schadmand-Fischer S, Schreckenberger M, Weber MM, Musholt TJ, Schroeder M, Miederer M (2025) Imaging-derived biomarkers from 68Ga-DOTATOC PET\/CT scans to predict survival of patients with neuroendocrine tumors after PRRT with 177Lu-DOTATATE. Cancer Imag 25(1):81. https:\/\/doi.org\/10.1186\/s40644-025-00899-5","journal-title":"Cancer Imag"},{"issue":"7","key":"307_CR60","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2967\/jnumed.121.262782","volume":"63","author":"RP Reddy","year":"2022","unstructured":"Reddy RP, Ross Schmidtlein C, Giancipoli RG, Mauguen A, LaFontaine D, Schoder H, Bodei L (2022) The quest for an accurate functional tumor volume with 68Ga-DOTATATE PET\/CT. J Nucl Med 63(7):1027\u20131032. https:\/\/doi.org\/10.2967\/jnumed.121.262782","journal-title":"J Nucl Med"},{"issue":"2","key":"307_CR61","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2214\/AJR.18.19881","volume":"211","author":"Y Sanli","year":"2018","unstructured":"Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM (2018) Neuroendocrine tumor diagnosis and Management: 68Ga-DOTATATE PET\/CT. Am J Roentgenol 211(2):267\u2013277. https:\/\/doi.org\/10.2214\/AJR.18.19881","journal-title":"Am J Roentgenol"},{"issue":"11","key":"307_CR62","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s11548-023-02968-1","volume":"18","author":"A Santilli","year":"2023","unstructured":"Santilli A, Panyam P, Autz A, Wray R, Philip J, Elnajjar P, Swinburne N, Mayerhoefer M (2023) Automated full body tumor segmentation in DOTATATE PET\/CT for neuroendocrine cancer patients. Int J CARS 18(11):2083\u20132090. https:\/\/doi.org\/10.1007\/s11548-023-02968-1","journal-title":"Int J CARS"},{"issue":"11","key":"307_CR63","doi-asserted-by":"publisher","first-page":"115009","DOI":"10.1088\/1361-6560\/add9df","volume":"70","author":"B Schott","year":"2025","unstructured":"Schott B, Santoro-Fernandes V, Klanecek \u017d, Perlman S, Jeraj R (2025) Uncertainty quantification for deep learning-based metastatic lesion segmentation on whole body PET\/CT. Physics in medicine and biology. 2025. Phys Med Biol 70(11):115009. https:\/\/doi.org\/10.1088\/1361-6560\/add9df","journal-title":"Phys Med Biol"},{"key":"307_CR64","unstructured":"Sengupta S, Yilmaz B, Meyer CC, Mallak N, Mittra E (2024) Predicting response to 177Lu-DOTATATE therapy for NETs using radiomic features from pre-and post-therapy DOTATATE PET\/CTs. J Nucl Med 65(Supplement 2)"},{"key":"307_CR65","doi-asserted-by":"publisher","unstructured":"Stadler TM, Hullner MW, Broglie MA, Morand GB (2020) Predictive value of suvmax changes between two sequential post-therapeutic FDG-pet in head and neck squamous cell carcinomas. Sci Rep 10(1):10(1).10.1038\/s41598\u2013020\u201373914\u20133. https:\/\/doi.org\/10.1038\/s41598-020-73914-3","DOI":"10.1038\/s41598-020-73914-3"},{"key":"307_CR66","doi-asserted-by":"publisher","first-page":"108827","DOI":"10.1016\/j.compbiomed.2024.108827","volume":"179","author":"A Stefano","year":"2024","unstructured":"Stefano A (2024) Challenges and limitations in applying radiomics to PET imaging: possible opportunities and avenues for research. Comput Biol Med 179:108827. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.108827","journal-title":"Comput Biol Med"},{"key":"307_CR67","doi-asserted-by":"publisher","unstructured":"Stokmo HL, Aly M, Bowitz Lothe IM, Borja AJ, Mehdizadeh Seraj S, Ghorpade R, Miao X, Hjortland GO, Malinen E, Sorbye H, Werner TJ, Alavi A, Revheim M-E (2022) Volumetric parameters from [18F]FDG PET\/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. J Neuroendocrinol 34(7):e13170. https:\/\/doi.org\/10.1111\/jne.13170","DOI":"10.1111\/jne.13170"},{"key":"307_CR68","doi-asserted-by":"publisher","unstructured":"Sultana Q, Kar J, Verma A, Sanghvi S, Kaka N, Patel N, Sethi Y, Chopra H, Kamal MA, Greig NH (2023) A comprehensive review on neuroendocrine neoplasms: presentation, pathophysiology and Management. JCM 12(15):5138.10.3390\/jcm12155138. https:\/\/doi.org\/10.3390\/jcm12155138","DOI":"10.3390\/jcm12155138"},{"issue":"10","key":"307_CR69","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2967\/jnumed.124.269349","volume":"66","author":"JJ Sunderland","year":"2025","unstructured":"Sunderland JJ, Boellaard R, Dickson JC, Graves SA, Bailey DL (2025) Standardization of PET\/CT performance requirements for whole-body quantitative imaging: an International Proposal. J Nucl Med 66(10):1506\u20131515. https:\/\/doi.org\/10.2967\/jnumed.124.269349","journal-title":"J Nucl Med"},{"key":"307_CR70","doi-asserted-by":"publisher","unstructured":"Tendler S, Dunphy M, Gopalan A, O\u2019Donoghue JA, Lyashchenko SK, Bodei L, Sch\u00f6der H, Autio KA, Poirier JT, Morris MJ, Rudin CM, Lewis JS (2025) Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with neuroendocrine tumors of the prostate: a phase 1\/2, first-in-human trial. JCO 43(16_suppl). https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e15057","DOI":"10.1200\/JCO.2025.43.16_suppl.e15057"},{"issue":"7","key":"307_CR71","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.121.262652","volume":"63","author":"P Thuillier","year":"2022","unstructured":"Thuillier P, Liberini V, Grimaldi S, Rampado O, Gallio E, De Santi B, Arvat E, Piovesan A, Filippi R, Abgral R, Molinari F, Deandreis D (2022) Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC PET\/CT in well-differentiated neuroendocrine tumors. J Nucl Med 63(7):1014\u20131020. https:\/\/doi.org\/10.2967\/jnumed.121.262652","journal-title":"J Nucl Med"},{"key":"307_CR72","doi-asserted-by":"publisher","unstructured":"Tien C, Yedavalli R (2016) Clinical significance of different contouring software on formalism-based Y-90 dose prescriptions. Int J Multiling Radiat Oncol*Biol*Phys 96(2):E647. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.06.2248","DOI":"10.1016\/j.ijrobp.2016.06.2248"},{"issue":"4","key":"307_CR73","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1053\/j.gastro.2017.11.008","volume":"154","author":"A Tirosh","year":"2018","unstructured":"Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E (2018) Prognostic utility of total 68Ga-DOTATATE-Avid tumor volume in patients with neuroendocrine tumors. Gastroenterology 154(4):998\u20131008.e1. https:\/\/doi.org\/10.1053\/j.gastro.2017.11.008","journal-title":"Gastroenterology"},{"key":"307_CR74","doi-asserted-by":"publisher","unstructured":"Veenstra EB, Brouwers AH, de Groot DJA, Hofland J, Walenkamp AME, Brabander T, Zandee WT, Noordzij W (2022) Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy. Eur J Hybrid Imag 6(1):6.10.1186\/s41824\u2013022\u201300133\u20136. https:\/\/doi.org\/10.1186\/s41824-022-00133-6","DOI":"10.1186\/s41824-022-00133-6"},{"issue":"1","key":"307_CR75","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13550-021-00839-x","volume":"11","author":"J Wehrend","year":"2021","unstructured":"Wehrend J, Silosky M, Xing F, Chin BB (2021) Automated liver lesion detection in 68Ga DOTATATE PET\/CT using a deep fully convolutional neural network. EJNMMI Res 11(1):98. https:\/\/doi.org\/10.1186\/s13550-021-00839-x","journal-title":"EJNMMI Res"},{"key":"307_CR76","doi-asserted-by":"publisher","unstructured":"Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester H-J, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M (2021) CXCR4-Directed PET\/CT in patients with newly diagnosed neuroendocrine carcinomas. Diagnostics 11(4):605.10.3390\/diagnostics11040605. https:\/\/doi.org\/10.3390\/diagnostics11040605","DOI":"10.3390\/diagnostics11040605"},{"key":"307_CR77","unstructured":"WHO Classification of Tumours Editorial Board (2022) WHO classification of endocrine and neuroendocrine tumours. IARC, Lyon, France"},{"issue":"6","key":"307_CR78","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Cutsem EV, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, \u00d6berg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514\u2013523. https:\/\/doi.org\/10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"issue":"1","key":"307_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2024.0507","volume":"22","author":"S Ye","year":"2025","unstructured":"Ye S, Li J, Xu J (2025) Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects. Cancer Biol Med 22(1):1\u20137. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0507","journal-title":"Cancer Biol Med"},{"issue":"4","key":"307_CR80","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000517530","volume":"112","author":"J Yu","year":"2022","unstructured":"Yu J, Cao F, Zhao X, Xie Q, Lu M, Li J, Yang Z, Sun Y (2022) Correlation and comparison of somatostatin receptor type 2 Immunohistochemical scoring Systems with 68Ga-DOTATATE Positron Emission Tomography\/Computed Tomography imaging in Gastroenteropancreatic neuroendocrine neoplasms. Neuroendocrinology 112(4):358\u2013369. https:\/\/doi.org\/10.1159\/000517530","journal-title":"Neuroendocrinology"},{"key":"307_CR81","doi-asserted-by":"crossref","unstructured":"Zhang C, Gudmundsdottir H, Takahashi H, Day C, Glasgow A, Wasif N et al (2023) Accuracy of DOTATATE PET imaging in the Preoperative planning of small bowel neuroendocrine tumor resection. In NANETS, 2023 Symposium, Montreal","DOI":"10.1002\/jso.27413"},{"issue":"4","key":"307_CR82","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/OP.21.00240","volume":"18","author":"JY Zhang","year":"2022","unstructured":"Zhang JY, Kunz PL (2022) Making sense of a complex disease: a practical Approach to managing neuroendocrine tumors. JCO Oncol Pract 18(4):258\u2013264. https:\/\/doi.org\/10.1200\/OP.21.00240","journal-title":"JCO Oncol Pract"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-026-00307-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:03:27Z","timestamp":1783289007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41824-026-00307-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1186\/s41824-026-00307-6","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DLC and JWTC were funded by the Cancer Institute NSW Early Career Fellowship. DLC reported honoraria from Ipsen, Novartis, Camurus, and research support from EMD Serono, outside the submitted work. NP reported personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Serono, Ipsen, Amgen, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Roche Pharma AG, Merck, Baxalta, and Specialised Therapeutics, outside the submitted work. The other authors have no potential conflicts of interest relevant to this study to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}